A 41-year-old female patient is being treated for obsessive-compulsive disorder (OCD). She is in exposure-response therapy (ERT) and is frustrated by the time it is taking for her to develop any meaningful improvement. She is now being started on fluoxetine as an augment to her therapy. It is important to advise her that: 

A. It is critical that she not stop taking fluoxetine abruptly due to concerns about discontinuation syndrome 

B. Success rates are very low but there may be some minimal improvement in combination with ERT therapy 

C. She will likely need a higher dose and longer duration than patients taking fluoxetine for depression 

D. The primary advantage of fluoxetine over other SSRIs for OCD is the low risk of drug interactions.